[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67(1): 328-357. [2] Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 . J Hepatol, 2018, 69(4): 896-904. [3] Tourkochristou E, Assimakopoulos SF, Thomopoulos K, et al. NAFLD and HBV interplay - related mechanisms underlying liver disease progression. Front Immunol, 2022, 13:965548. [4] Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Front Nutr, 2022, 9(1047129. [5] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. [6] Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016, 65(3): 589-600. [7] Cen J, Wang Q, Cheng L, et al. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain, 2024, 25(1): 96. [8] Kan C, Zhang K, Wang Y, et al. Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045. Ann Hepatol, 2025, 30(2): 101898. [9] Han X, Ding S, Lu J, et al. Global, regional, and national burdens of common micronutrient deficiencies from 1990 to 2019: A secondary trend analysis based on the Global Burden of Disease 2019 study. E Clin Med, 2022, 44(101299. [10] Wang J, Du J, Wang M, et al. Global, regional, and national burden of NAFLD in youths and young adults aged 15-39 years, 1990-2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021. Front Nutr, 2025, 12:1509232. [11] Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev, 2012, 70(1): 3-21. [12] Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 393(10184): 1958-1972. [13] Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol, 2018, 68(5): 1063-1075. [14] Ng SW, Popkin BM. Time use and physical activity: a shift away from movement across the globe. Obes Rev, 2012, 13(8): 659-680. [15] Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet, 2017, 390(10113): 2627-2642. [16] Amorim JA, Coppotelli G, Rolo AP, et al. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol, 2022, 18(4): 243-258. [17] Wong WK, Chan WK. Nonalcoholic fatty liver disease: A global perspective. Clin Ther, 2021, 43(3): 473-499. [18] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018, 18(3): 245-250. [19] Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet, 2023, 402(10397): 203-234. [20] Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet, 2025, 405(10481): 813-838. [21] Gu Y, Guo C, Liu Z, et al. The trend in incidence of non-alcoholic fatty liver disease and its impact on cirrhosis and liver cancer: An analysis from Global Burden of Disease 2021. Public Health, 2025, 242:79-86. [22] Tan DJH, Setiawan VW, Ng CH, et al. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. Hepatology, 2023, 77(4): 1150-1163. |